Scott Minick Net Worth

The estimated Net Worth of Scott Minick is at least $477 Tausend dollars as of 19 August 2019. Mr. Minick owns over 9,818 units of Chiasma Inc stock worth over $327,849 and over the last 9 years he sold CHMA stock worth over $0. In addition, he makes $149,630 as Independent Director at Chiasma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Minick CHMA stock SEC Form 4 insiders trading

Scott has made over 3 trades of the Chiasma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 9,818 units of CHMA stock worth $50,955 on 19 August 2019.

The largest trade he's ever made was buying 25,000 units of Chiasma Inc stock on 18 September 2018 worth over $77,000. On average, Scott trades about 5,982 units every 70 days since 2015. As of 19 August 2019 he still owns at least 87,194 units of Chiasma Inc stock.

You can see the complete history of Mr. Minick stock trades at the bottom of the page.

Scott Minick biography

Scott Minick is an Independent Director of the Company. He joined our Board of Directors in October 2007. From January 2010 to March 2015, Mr. Minick served as President and Chief Executive Officer of BIND Therapeutics, Inc. (NASDAQ: BIND), or BIND, a biopharmaceutical company. From 1998 to 2010, Mr. Minick was Managing Director of ARCH Venture Partners, or ARCH, and from 2010 to the present he has been Venture Partner of ARCH, where he was instrumental in the startup, development and financing of numerous ARCH portfolio companies, including BIND and Chiasma. From 1995 to 1998, Mr. Minick was Director, President and Chief Operating Officer of SEQUUS Pharmaceuticals, Inc. (NASDAQ:SEQU), a biopharmaceutical company that was acquired by ALZA Corporation. Mr. Minick was formerly an executive at Baxter International, Inc. (NYSE: BAX) and Eli Lilly & Company (NYSE: LLY). He serves as a member of the board of directors of Alzheon, Inc. and Aira Tech Corp., served as a member of the board of directors of BIND from 2007 to 2015 and is a trustee of Beth Israel Deaconess Medical Center. Mr. Minick received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University, and a B.A. from the University of California, San Diego.

What is the salary of Scott Minick?

As the Independent Director of Chiasma Inc, the total compensation of Scott Minick at Chiasma Inc is $149,630. There are 8 executives at Chiasma Inc getting paid more, with Raj Kannan having the highest compensation of $6,413,280.

How old is Scott Minick?

Scott Minick is 68, he's been the Independent Director of Chiasma Inc since 2007. There are 2 older and 10 younger executives at Chiasma Inc. The oldest executive at Chiasma Inc is John Scarlett, 69, who is the Independent Director.

What's Scott Minick's mailing address?

Scott's mailing address filed with the SEC is C/O CHIASMA, INC., 140 KENDRICK STREET, BUILDING C EAST, NEEDHAM, MA, 02494.

Insiders trading at Chiasma Inc

Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke und John F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.

What does Chiasma Inc do?

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.

Complete history of Mr. Minick stock trades at Chiasma Inc

Chiasma Inc executives and stock owners

Chiasma Inc executives and other stock owners filed with the SEC include:

• Raj Kannan,
  Chief Executive Officer, Director
• anand Varadan,
  Executive Vice President, Chief Commercial Officer
• Mark Fitzpatrick,
  President, Chief Financial Officer
• William Ludlam,
  Senior Vice President - Clinical Development and Medical Affairs
• Lee Giguere,
  Vice President, General Counsel, Secretary
• Drew Enamait,
  Vice President, Finance and Administration, Principal Accounting Officer
• Roni Mamluk,
  Director
• David Stack,
  Independent Chairman of the Board
• Scott Minick,
  Independent Director
• John Scarlett,
  Independent Director
• John Thero,
  Independent Director
• Todd Foley,
  Independent Director
• Bard Geesaman,
  Independent Director
• Ashley Robinson,
  IR Contact Officer
• Health Ventures Lp Wertheim...,
  
• Bio Ventures Iv Qp Lpevnin ...,
  
• Ansbert Gadicke,
  Director
• Mark Leuchtenberger,
  CEO, President
• James R Tobin,
  Director
• Tara Mc Carthy,
  General Counsel and Secretary
• Vincent J Miles,
  Director
• Llp Abingworth,
  10% owner
• John Brendan Doyle,
  Chief Financial Officer
• Capital, L.P. Stonepine,
  10% owner